Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 4, 2000, Pages 33-38

  Keck Jr , Paul E ^a   McElroy, Susan L ^a   Strakowski, Stephen M ^a   Soutullo, Cesar A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID;

AFFECTIVE NEUROSIS; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MANIA; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; TARDIVE DYSKINESIA;

ACUTE DISEASE; AFFECTIVE DISORDERS, PSYCHOTIC; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIPOLAR DISORDER; CLINICAL TRIALS; DYSKINESIA, DRUG-INDUCED; HUMANS; HYPERPROLACTINEMIA; MULTICENTER STUDIES; PROLACTIN; RISK FACTORS;

EID: 0342470537     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
2. Suppes T, Leverich GS, Keck PE Jr, et al. The Stanley Foundation Bipolar Treatment Outcome Network, II: demographics and illness characteristics of the first 261 patients. J Affect Disord. In press
3. Schatzberg AF, Rothchild AJ. Psychotic (delusional) depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992;149: 733-745
4. Keck PE Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998;59 (suppl 6):74-81
5. Carlson GA, Goodwin FK. The stages of mania: a longitudinal analysis of the manic episode. Arch Gen Psychiatry 1973;28:221-228
6. Pope HG Jr, Lipinski JF. Diagnosis in schizophrenia and manic-depressive illness: a reassessment of the specificity of schizophrenic symptoms in the light of current research. Arch Gen Psychiatry 1978;35:811-828
7. Tohen M, Tsuang MT, Goodwin DT. Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features. Am J Psychiatry 1992;149:1580-1584
8. Andreasen NC. Thought, language and communication disorders, II: diagnostic significance. Arch Gen Psychiatry 1977;36:1325-1330
9. Coryell W, Pfohl B, Zimmerman M. The clinical and neuroendocrine features of psychotic depression. J Nerv Ment Dis 1984;172:521-528
10. Rothchild AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am 1996;19:237-255
11. Licht RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand 1998;97:387-397
12. McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996;57(suppl 3):14-26
13. Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. J Clin Psychiatry 1996;57(suppl 9):49-52
14. Keck PE Jr, McElroy SL. Pharmacologic treatment of bipolar disorders. In: Nathan PE, Gorman JM, eds. A Guide to Treatments That Work. New York. NY: Oxford University Press; 1998:249-269
15. Klein DF, Oak G. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967;16:118-126
16. Johnson G, Gerson S, Burdock EI, et al. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry 1971;119:267-276
17. Spring G, Schweid D, Gray C, et al. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. Am J Psychiatry 1970;127:351-353
18. Platman SR. A comparison of lithium carbonate and chlorpromazine in mania. Am J Psychiatry 1970;127:351-353
19. Prien RF, Caffey EM Jr, Klett CJ, et al. Comparison of lithium carbonate and chlorpromazine in the treatment of mania: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1972;26:146-153
20. Shopsin B, Gerson S, Thompson H, et al. Psychoactive drugs in mania: a controlled comparison of lithium carbonate, chlorpromazine and haloperidol. Arch Gen Psychiatry 1975;32:34-42
21. McElroy SL, Keck PE Jr, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142-146
22. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979;66:211-217
23. Grossi E, Saccetti E, Vita A. Carbamazepine vs chlorpromazine in mania: a double-blind trial. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam, the Netherlands: Excerpta Medica; 1984:177-187
24. Janicak PG, Newman RH, Davis JM. Advances in the treatment of manic and related disorders: a reappraisal. Psychiatr Ann 1992;22:94-98
25. Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998;59(suppl 1):38-48
26. Suppes T, Rush AJ, Webb A, et al. A randomized, controlled trial of clozapine versus treatment as usual in refractory bipolar disorder. Presented at the 51st annual meeting of the Society for Biological Psychiatry; May 4, 1996; New York, NY
27. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176-180
28. Tohen M, Sanger T, Tollefson GD, et al. Olanzapine vs. placebo in the treatment of acute mania. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; Dec 8-12, 1997; Honolulu, Hawaii
29. Zarate CA Jr, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995;56:411-117
30. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-764
31. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled sludy. Arch Gen Psychiatry 1991;48: 62-68
32. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 1994;271:918-924
33. Keck PE Jr, McElroy SL, Strakowski SM. Schizoaffective disorder: role of atypical antipsychotics. Schizophr Res 1999;35:S5-S12
34. Keck PE Jr, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995;56:466-470
35. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-429
36. Banov MD, Zarate CA Jr, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300
37. Zarate CA Jr, Narendran R, Tohen M. et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998;59:24-28
38. Chou JC-Y, Zito JM, Vitrai J, et al. Neuroleptics in acute mania: a pharmacoepidemiologic study. Ann Pharmacother 1996;30:1396-1398
39. Sachs GS. Use of clonazepam for bipolar affective disorder. J Clin Psychiatry 1990;51(5, suppl):31-34
40. Sernyak MJ, Griffin RA, Johnson RM, et al. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am J Psychiatry 1994;151:133-135
41. Keck PE Jr, McElroy SL, Strakowski SM, et al. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996;57:147-151
42. Verdoux H, Gonzales B, Takei N, et al. A survey of prescribing practice of antipsychotic maintenance treatment foi manic-depressive outpatients. J Affect Disord 1996;57:143-147
43. White E, Cheung T, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8:119-122
44. Naylor GJ, Scott CR, Depot injections for affective disorders. Br J Psychiatry 1980;136:105
45. Lowe MR, Batchelor DH. Lithium and neuroleptics in the management of manic depressive psychosis. Hum Psychopharmacol 1990;5:267-274
46. Lowe MR, Batchelor DH. Depot neuroleptics and manic depressive psychosis. Int Clin Psychopharmacol 1986;1(suppl 1):53-62
47. Littlejohn R, Leslie FM, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 1994;165:827-829
48. Ahlfors UG, Baastrup PC, Denckes SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981;64:226-237
49. Esparon J, Kallaori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148:723-725
50. Morgan HG. The incidence of depressive symptoms during recovery from hypomania. Br J Psychiatry 1972;120:537-539
51. Kukopulos A, Reginaldi D, Laddomana P, et al. Course of manic-depressive cycle and changes caused by treatments. Pharmacopsychiatr Neuropsychopharmacol 1980;13:156-167
52. Kane JM, Jeste DV, Barnes TRE, et al. Tardive Dyskinesia: a Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Press; 1992
53. Mukherjee S, Rosen AM, Caracci G, et al. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986;43:342-346
54. Nasrallah HA, Churchill CM, Handan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than schizophrenia. Am J Psychiatry 1988;145:1455-1456
55. Tohen M. Olanzapine vs placebo in the treatment of acute mania. Presented at the 151st annual meeting of the American Psychiatric Association; May 31, 1998: Toronto, Ontario, Canada
56. Lieberman JA, Sultz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510
57. Collaborative Working Group on Clinical Trial Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998;59 (suppl 12):23-27
58. Davidson M, for the Risperidone Working Group. Long-term efficacy, safety, and tolerability of risperidone in elderly psychotic patients. Presented at the 12th annual symposium of the American Association for Geriatric Psychiatry: March 14-17, 1999; New Orleans, La
59. Soutullo CA, Keck PE Jr, McElroy SL. Olanzapine in the treatment of tardive dyskinesia: a report of two cases. J Clin Psychopharmacol 1998;140: 173-184
60. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-436
61. Parker G, Roy K, Hadzi-Pavlovic D, et al. Psychotic (delusional) depression: a meta-analysis of physical treatment. J Affect Disord 1992;24:17-24
62. Anton RF, Burt EZ. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990; 147:1203-1208
63. Aronson TA, Shukla S, Gujavarty K, et al. Relapse in delusional depression: a retrospective study of the course of treatment. Compr Psychiatry 1988;29:12-21
64. Clower CG. Recurrent psychotic unipolar depression. J Clin Psychiatry 1983;44:216-218
65. Davis K, Berger P, Hollister L. Tardive dyskinesia and depressive illness. Psychopharmacol Comm 1976;2:125-130
66. Rosenbaum AH, Niven RG, Hanson HP, et al. Tardive dyskinesia: relationship with primary affective disorder. Dis Nerv Syst 1977;38:423-426
67. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481
68. Rush M, Diamond F, Alpert M. Depression as a risk factor in tardive dyskinesia. Biol Psychiatry 1982;17:387-392
69. Yassa R, Ghadirian AM, Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry 1983;44:410-412
70. Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984;25:135-138
71. Mukherjee S, Rosen AM, Caracci G. et al. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986;43:342-346
72. Waddington JL, Youssef HA. Tardive dyskinesia in bipolar affective disorder: aging, cognitive dysfunction, course of illness, and exposure to neuroleptics and lithium. Am J Psychiatry 1988;145:613-616
73. Waddington JL, Brown K, O'Neill J, et al. Cognitive impairment, clinical course and treatment history in out-patients with bipolar affective disorder: relationship to tardive dyskinesia. Psychol Med 1989;19:897-902
74. Dinan TG, Kohen D. Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy. Br J Psychiatry 1989;155:55-57
75. Axelsson R, Nilsson A. On the pathogenesis of abnormal involuntary movements in lithium-treated patients with major affective disorder. Eur Arch Psychiatry Clin Neurosci 1991;241:1-7
76. Ghadirian A-M, Annable L, Belanger M-C. et al. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 1996;57:22-28
77. Cutler NR, Post RM, Rey A, et al. Depression-dependent dyskinesias in two cases of manic-depressive illness. N Engl J Med 1981;304:1088-1089
78. Applebaum PS. Dyskinesia and unipolar depression. Am J Psychiatry 1982;139:140-141
79. Weiner WJ, Werner TR. Mania-induced remission of tardive dyskinesia in manic-depressive illness. Ann Neurol 1982;12:229-230
80. DePotter RW, Linkowski P, Mendlewicz J. State-dependent tardive dyskinesia in manic-depressive illness. J Neurol Neurosurg Psychiatry 1983; 46:666-668
81. Linnoila M, Karoum F, Cutler NR, et al. Temporal association between depression-dependent dyskinesias and high urinary phenylethylamine output. Biol Psychiatry 1983;18:513-516
82. Keshavan MS, Goswamy W. Tardive dyskinesia less severe in depression. Br J Psychiatry 1983;142:207-208
83. Lal KP, Saxena S, Mohan D. Tardive dystonia alternating with mania. Biol Psychiatry 1988;23:312-316
84. Sachdev PS. Depression-dependent exacerbation of tardive dyskinesia. Br J Psychiatry 1989;155:253-255
85. Yazici O, Kantemir E, Tastaban Y. et al. Spontaneous improvement of tardive dystonia during mania. Br J Psychiatry 1991;158:847-850
86. Casey D. Tardive dyskinesia and affective disorders. In: Gardos G. Casey DE, eds. Tardive Dyskinesia and Affective Disorders. Washington, DC: American Psychiatric Press; 1984:1-20
87. Wegner JT, Catalano F, Gibralter J, et al. Schizophrenics with tardive dyskinesia: neuropsychological deficit and family psychopathology. Arch Gen Psychiatry 1985;42:860-865
88. Wegner JT, Kane JM, Weinhold P, et al. Cognitive impairment in tardive dyskinesia. Psychiatry Res 1985;16:331-337
89. Richardson MA, Pass R, Bregman Z, et al. Tardive dyskinesia: relationship with primary affective disorder. Dis Nerv Syst 1977;38:423-426
90. Tsuang MT, Faraone SV. The Genetics of Mood Disorders. Baltimore. Md: The Johns Hopkins University Press; 1990
91. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15 (suppl 1):36-44
92. Brecher M. Long-term safety of risperidone [abstract]. Eur Neuropsychopharmacol 1996;6(suppl 3):170
93. Beasley CM, Dellva MA, Tamura RN. et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30